InvestorsObserver
×
News Home

BioNTech SE (BNTX) and Pfizer Inc. (PFE) Announce Phase 3 Trial Data for Covid-19 Booster; Shares Mixed

Thursday, October 21, 2021 10:05 AM | Kyle Depontes

Mentioned in this article

BioNTech SE (BNTX) and Pfizer Inc. (PFE) Announce Phase 3 Trial Data for Covid-19 Booster; Shares Mixed

What is going on for BNTX?

BioNTech SE (BNTX) and Pfizer, Inc. (PFE) today announced topline results from a Phase 3 trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine in more than 10,000 individuals 16 years of age and older.

The trial results showed that a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series restored vaccine protection against COVID-19 to the levels achieved after the second dose.

Shares of BNTX increased 2.93% to $277.18, while shares of PFE declined 0.77% to $42.47 as of Thursday at 9:55 am.

What does this mean for BioNTech?

Pfizer and BioNTech plan to submit results from the trial for peer-reviewed publication and will share the data with the FDA, European Medicines Agency, and other regulatory agencies around the world as soon as possible.

However, Pfizer's booster dose of its COVID-19 Vaccine is already authorized for emergency use by the FDA for most groups, including individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.

Albert Bourla, Chairman and CEO of Pfizer, commented, “In addition to our efforts to increase global access and uptake among the unvaccinated, we believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic."

"We look forward to sharing these data with health authorities and working together to determine how they can be used to support the rollout of booster doses around the world.”

The median age in the trials was 53 years, with 23.3% of participants 65 years and older.

Sentiment Score - ,bullish

BioNTech SE - ADR has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on BNTX!

BioNTech SE is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App